
Immunomedics announced on 10 February that it had entered a licensing agreement with Seattle Genetics for its leading experimental cancer …
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

